Sugi Predict

Sugi Predict / Compounds / SCHEMBL1734546

SCHEMBL1734546

SCHEMBL1734546

CCC(CC(=O)O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ EPHX2 P34913 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ FFAR1 O14842 4/20 0.44
▸ FNTA P49354 1/20 0.43
▸ FNTB P49356 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ EEF2K O00418 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ FPR2 P25090 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734544 1.00 CA12 (0.46) CA12CA1MMP2MEN1KMT2A
SCHEMBL14509044 0.88 CA12 (0.46) CA12CA1MMP2MEN1KMT2A
SCHEMBL3265463 0.87 KIF11 (0.45) CA12CA1MMP2MEN1KMT2A
SCHEMBL8996214 0.87 KIF11 (0.45) CA12CA1MMP2MEN1KMT2A
SCHEMBL1937094 0.87 KIF11 (0.45) CA12CA1MMP2MEN1KMT2A
SCHEMBL4811641 0.86 HDAC1 (0.44) CA12CA1MMP2MEN1KMT2A
SCHEMBL5516712 0.86 HDAC1 (0.44) CA12CA1MMP2MEN1KMT2A
SCHEMBL3264263 0.85 CA12 (0.44) CA12CA1MMP2MEN1KMT2A
SCHEMBL3264266 0.85 CA12 (0.44) CA12CA1MMP2MEN1KMT2A
SCHEMBL3267002 0.85 CA12 (0.44) CA12CA1MMP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084611-B2 Process for preparing tetrahydroquinoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-12-27 — — US claimed
EP-2007728-B1 A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES MITSUBISHI TANABE PHARMA CORP (JP) 2011-11-16 — — EP claimed
WO-2011131370-A1 MELT-GRANULATED FINGOLIMOD RATIOPHARM GMBH (DE) 2011-10-27 — — WO claimed
US-20090292125-A1 PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-26 — — US claimed
CN-101466679-A Process for preparing tetrahydroquinoline derivatives MITSUBISHI TANABE PHARMA CORP (JP) 2009-06-24 — — CN claimed
EP-2007728-A1 A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES Mitsubishi Tanabe Pharma Corporation (JP) 2008-12-31 — — EP claimed
WO-2007116922-A1 A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 — — WO claimed
EP-1604975-A1 PROCESSES FOR PRODUCTION OF (R)-3- 4-(TRIFLUOROMETHYL)- PHEN YLAMINO PENTANAMIDE DERIVATIVES KANEKA CORPORATION (JP) 2005-12-14 — — EP claimed
US-20040199005-A1 Method for producing (R) -3- [4- (trifluoromethyl) phenylamino] -pentanoic acid amide derivative KANEKA CORPORATION (JP) 2004-10-07 — — US claimed
CN-103210047-B The diazene * dioxide of the substitution containing N and/or the aqueous polishing composition of N '-hydroxyls-diazene * oxide salts 巴斯夫欧洲公司 2018-07-17 — — CN disclosed
CN-103080256-B Aqueous polishing composition and process for chemically mechanically polishing substrates containing silicon oxide dielectric and polysilicon films BASF SE 2015-06-24 — — CN disclosed
EP-1594843-B1 METHOD FOR PRODUCING AN OPTICALLY ACTIVE beta-amino acid derivative TAKASAGO PERFUMERY CO LTD (JP) 2013-05-22 — — EP disclosed
US-8188307-B2 Method for producing an optically active tetrahydroquinoline TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-05-29 — — US disclosed
US-8084611-B2 Process for preparing tetrahydroquinoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-12-27 — — US disclosed
EP-2007728-A1 A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES Mitsubishi Tanabe Pharma Corporation (JP) 2008-12-31 — — EP disclosed
WO-2007116922-A1 A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 — — WO disclosed
US-7223859-B2 Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative PFIZER INC. (US) 2007-05-29 — — US disclosed
US-20060122225-A1 Method for producing an optically active tetrahydroquinoline TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-06-08 — — US disclosed
EP-1604975-A1 PROCESSES FOR PRODUCTION OF (R)-3- 4-(TRIFLUOROMETHYL)- PHEN YLAMINO PENTANAMIDE DERIVATIVES KANEKA CORPORATION (JP) 2005-12-14 — — EP disclosed
US-20040199005-A1 Method for producing (R) -3- [4- (trifluoromethyl) phenylamino] -pentanoic acid amide derivative KANEKA CORPORATION (JP) 2004-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040199005-A1 Method for producing (R) -3- [4- (trifluoromethyl) phenylamino] -pentanoic acid amide derivative CETP, PCTP, MTTP CA12 3484/4885CA1 2155/4885MMP2 1518/4885
US-20090292125-A1 PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES PCSK9, LSS, DHCR7 CA12 4868/4885CA1 4848/4885MMP2 3990/4885
US-20060122225-A1 Method for producing an optically active tetrahydroquinoline AADAT, KMO, ALDH7A1 CA12 2615/4885CA1 1662/4885MMP2 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.